abelheira schreef op 10 januari 2017 08:45:
[...]
"And so, I want to finish up with inflammation just quickly. Excuse me, looking at filgotinib, that’s our selective JAK-1 inhibitor. We talked about this last year. It has a very large safety database of over 900 patients. It’s once-daily and we think it has some very pronounced advantages in terms of being well-tolerated and useful across a wide range of different diseases.
We have now, since last year, initiated Phase III studies in rheumatoid arthritis, ulcerative colitis and RA, we have about 6,000 patients slated to be enrolled in
six major clinical studies.
This just looks at the different studies that we’re doing, looking at methotrexate-naïve, methotrexate-inadequate responders, and biologic inadequate responders in RA. We think this could be one of the first drugs approved in Crohn’s disease of the JAK category because of the pronounced effect we saw on Phase II. We went into the Phase III immediately. So,
we’re very, very excited about moving forward with filgotinib."
Er is sprake van 6 klinische onderzoeken!